Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2584702 · 1 trial · 1 indication
A clinically significant effect was any event that was a dose-limiting toxicity event (DLT). DLT was defined as an adverse event related to LY2584702 during Cycle 1 (Day 1 to Day 30) that fulfills any one of the following criteria; Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 non-hematological toxicity; platelet count \<50.0 x 10\^9/Liter (L) with bleeding; CTCAE Grade 4 platelet count decreased; neutrophil count \<0.5 x 10\^9/L lasting for 5 days or longer; any febrile neutropenia; CTCAE Grade 4 anemia; participant risk due to increasing toxicity.
| Arm | Type | Description |
|---|---|---|
| LY2584702 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY2584702 | DRUG | Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle. Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met. |
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of advanced and/or metastatic cancer (solid tumors) that is refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists. * Have the presence of disease amena...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY2584702 is an investigational small molecule being studied for the treatment of cancer and for use in healthy participants. It was evaluated in Phase 1 clinical trials, including a study in patients with solid tumors and a single-dose study in healthy participants to assess safety and absorption.
LY2584702 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is an investigational small molecule that has been studied in early-stage clinical trials for oncology and healthy participant indications.
LY2584702 is in Phase 1 clinical development. It has completed two Phase 1 trials: one in patients with solid tumors in Japan and another in healthy participants in Singapore. The drug is investigational and not approved for any use.
LY2584702 has been studied in two completed Phase 1 trials. NCT01241461 evaluated the drug in patients with solid tumors in Japan, enrolling 9 participants. NCT01372085 was a single-dose study in healthy participants in Singapore, enrolling 29 participants. Both trials are completed.
LY2584702 is a small molecule being investigated for its potential anti-cancer activity. Its specific molecular target has not been disclosed in the available clinical trial information. The drug was studied in a Phase 1 trial for solid tumors and in a healthy participant study to evaluate its safety and absorption.